

AAIC® Advancements: Modernizing Diagnosis, Sept. 18-19, 2024 in Tokyo, Japan, and online, will bring together global leaders from across disciplines to discuss advances in the diagnosis of Alzheimer's and other dementias.

WEDNESDAY, SEPTEMBER 18, 2024

9-9:15 a.m.

Welcome
Galaxy

Joanne Pike, Alzheimer's Association, USA
Takeshi Iwatsubo, The University of Tokyo, Japan
Masami Sakoi, Chief Medical and Global Health Officer, Ministry of Health, Labour and Welfare

9:15-10:30 a.m.

Session: The Landscape for Diagnosis in Asia
Galaxy

Moderators:

Anna Barron, Nanyang Technological University of Singapore
Huali Wang, Peking University, China

Presenters:

The Landscape in Japan

Ryoji Noritake, Health and Global Policy Institute, Japan

The Landscape in China

Yong Shen, University of Science and Technology of China, China

The Landscape in The Republic of Korea

Jee Hyang Jeong, Ewha Womans University, Republic of Korea

The Landscape in Indonesia

Fasihah Irfani, Atlantic Fellow Global Brain Health Institute/Universitas Sumatera Utara, Indonesia

The Landscape in Thailand

Orapitchaya Sriwannopas, Mahidol University, Thailand

The Landscape in Taiwan

Chaur-Jong Hu, Taipei Medical University, Taiwan

The Landscape in Singapore

Christopher Chen, National University of Singapore, Singapore

An NIA Framework for Cross-National Comparisons of AD/ADRD Measurements to Modernize Diagnosis

Luke Stoeckel, National Institute on Aging, United States

10:30-11 a.m.

Break
Galaxy Foyer

11 a.m.-12 p.m.

Session: Revised Criteria for Diagnosis and Staging

Galaxy

Moderators:

Clifford Jack, Mayo Clinic, USA
Heather Snyder, Alzheimer's Association, USA

Presenters:

Overview of Revised Criteria for Alzheimer's Disease

Ozioma Okonkwo, University of Wisconsin-Madison, USA

Neuronal alpha-Synuclein Disease Integrated Staging System

Tanya Simuni, Northwestern University Feinberg School of Medicine, USA

Operationalization of Revised Criteria for Clinical Trials

Michael Rafii, University of Southern California, USA

Biological Definition of Disease Across Neurodegenerative Diseases: Similarities and Controversies

Clifford Jack, Mayo Clinic, USA

12-1:30 p.m.

Lunch and Networking

(In person only)

Galaxy D

1:30 p.m.-2:45 p.m.

Session: The Interplay and Integration of Biomarkers: Core Biomarkers and Co-Pathologies

Galaxy

Moderators:

Takeshi Ikeuchi, Niigata University, Japan
Henrik Zetterberg, University of Gothenburg, Sweden

Presenters:

Overview of Categories of Biomarkers

Henrik Zetterberg, University of Gothenburg, Sweden

Comparison of Autopsy Cohorts across Races and Ethnicities

Jun Pyo Kim, Samsung Medical Center, Republic of Korea

Biomarker Development in the Context of Comorbidities

Donna Wilcock, Indiana University School of Medicine, USA

Vascular Pathology

Nagaendran Kandiah, Nanyang Technological University, Singapore

2:45-3:15 p.m.

Lightning Presentation Round (Submitted Abstracts)

Galaxy

Moderator:

Oz Ismail, Alzheimer's Association, USA
James Brady, University of Tasmania, Australia

Presenters:

Differential Roles Of Alzheimer's Disease Plasma Biomarkers In Stepwise Biomarker-guided Diagnostics

Daeun Shin, Samsung Medical Center, Republic of Korea

[18F]fluorodeprenyl-f2 Pet Imaging For Early Detection Of Reactive Astrocytosis And Cognitive Decline In Alzheimer's Disease

Boris-Stephan Rauchmann, University Hospital, LMU Munich, Germany

Neuroigin-1 And Neuroigin-2 As New Blood Biomarkers For Prodromal Alzheimer's Disease

Jonathan Brouillette, University of Montreal, Canada

APOE4 Gene Dose Effect On Plasma Biomarkers And The Penetrance Of Alzheimer's Disease: A Longitudinal Community-based Study

Zhenxu Xiao, Institute of Neurology, Huashan Hospital, Fudan University, China

Validating The Utility Of Plasma Biomarkers To Diagnose Autopsy Confirmed Alzheimer's Disease

Jennifer Cooper, University of British Columbia, Canada

3:15–4:00 p.m.

Poster Break

Galaxy Foyer

4:00–5:30 p.m.

Session: Real-World Applications - Case Studies

Galaxy

Moderators:

Atsushi Iwata, Tokyo Metropolitan Institute of Gerontology, Japan
Seong Hye Choi, Inha University School of Medicine, Republic of Korea

Presenters:

Hanna Cho, Yonsei University College of Medicine, Republic of Korea
Jonathan Graff-Radford, Mayo Clinic, USA
Hisatomo Kowa, Kobe University Graduate School of Health Sciences, Japan
Ryoko Ihara, Tokyo Metropolitan Geriatric Medical Center Hospital, Japan
Tammie Benzinger, Washington University in Saint Louis, USA

Closing Remarks Day 1

Reisa Sperling, Harvard Medical School, USA

5:30–7:00 p.m.

Welcome Reception

Star

THURSDAY, SEPTEMBER 19, 2024

9-10:15 a.m.

Opening Remarks Day 2

Reisa Sperling, Harvard Medical School, USA

Session: Implications of Amyloid-Lowering Treatments

Galaxy

Moderators:

Rema Raman, University of Southern California, USA
Takeshi Iwatsubo, The University of Tokyo, Japan

Presenters:

Trials of Amyloid-Lowering Treatments in Japan

Yoshiki Niimi, The University of Tokyo, Japan

Characterisation of Treatment-Related Amyloid Clearance

Renaud La Joie, University of California, San Francisco, USA

ARIA In the Setting of Anti-amyloid Treatment

Jin Zhou, Eisai, Japan

Trajectories and Predictors of Treatment-Related Amyloid Clearance

Sergey Shcherbinin, Eli Lilly, USA

Implications for Trial Designs, Including Combination Therapies

Judith Heidebrink, University of Michigan, USA

10:15–11 a.m.

Poster Break

Galaxy Foyer

11 a.m.–12:30 p.m.

Session: Towards Earlier Diagnoses: Ethics and Opportunities for Secondary Prevention

Galaxy

Moderators:

Jianping Jia, Capital Medical University, China

Reisa Sperling, Harvard Medical School, USA

Presenters:

Biomarker Trajectories Preceding Alzheimer's Dementia

Jianping Jia, Capital Medical University, China

TRAILBLAZER 3

Roy Yaari, Eli Lilly and Company, USA

AHEAD 3-45

Reisa Sperling, Harvard Medical School, USA

Efficient and Sustainable Community Screening of Cognitive Impairment in Japan

Hidenori Arai, National Center for Geriatrics and Gerontology, Japan

Non-pharmacological approaches: a Global Perspective

Wiesje van der Flier, Amsterdam UMC, Netherlands

The Ethics of Preclinical Diagnosis

Joshua Grill, University of California Irvine, USA

NIA Perspectives

Laurie Ryan, National Institute on Aging, USA

12:30-1 p.m.

Lightning Presentation Round (Submitted Abstracts)

Galaxy

Moderator:

Oz Ismail, Alzheimer's Association, USA

James Brady, University of Tasmania, Australia

Presenters:

Early Predictors Of Medial Temporal Tau Pathology

Hadi Hosseini, Stanford University, USA

a β -pet Substantiates Clinical Decision-making In Real-life Clinical Settings In Brazil

Cristiano Schaffer Aguzzoli, Brain Institute of Rio Grande do Sul, Brazil

Detecting Alzheimer's Disease Using AI-assisted Virtual Reality Digital Cognitive Tests In Chinese Older Adults

Lili Fang, Shenzhen Bay Laboratory, China

Behavioral Reaction To Amyloid Status Disclosure Among High-AD Risk Research Participants

Sapir Golan Shekhtman, Sheba Medical Center, Israel

Validation Of Multiple Plasma Phospho-tau Assays For The Diagnosis Of Alzheimer's Disease In The Japanese Population

Masanori Kurihara, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan

1-2:15 p.m.

Lunch

Galaxy D

2:15-3:15 p.m.

Session: Can Blood Tests Stand Alone in Alzheimer's Disease Diagnosis?

Galaxy

Moderator:

Sebastian Palmqvist, Lund University, Sweden

Presenters:

Overview:

Sebastian Palmqvist, Lund University, Sweden

Panelist

Alicia Algeciras-Schimnich, Mayo Clinic, USA

Ding Ding, Fudan University Huashan Hospital, China

Fanny Ip, Hong Kong University of Science and Technology, Hong Kong

SangYun Kim, Seoul National University College of Medicine, Republic of Korea

3:15-3:30 p.m.

Awards and Close

Galaxy

Reisa Sperling, Harvard Medical School, USA

Takeshi Iwatsubo, The University of Tokyo, Japan

SAVE THE DATE

Join the Alzheimer's Association® at these upcoming dementia research events.

AAIC Advancements: Exploring Equity in Diagnosis

Nov. 18-19 | Chicago, USA, and Online

AAIC Neuroscience Next

Feb. 24-27, 2025 | Online

AAIC Advancements: APOE & Lipid Biology

March 17-18, 2025 | Miami, USA and Online

AAIC Satellite Symposium

May 14-15, 2025 | Lima, Peru, and Online

alz.org/scientificmeetings

Join the conversation



@alzassociation

AAICAdvancements

JOIN MORE THAN 10,000 MEMBERS OF ISTAART IN OVER 120 COUNTRIES AND ADVANCE YOUR CAREER AS PART OF A GLOBAL NETWORK



The Alzheimer's Association® International Society to Advance Alzheimer's Research and Treatment (ISTAART) is an inclusive global network of scientists, clinicians and dementia professionals. Members of this professional organization share common goals: the pursuit of knowledge, collaboration and breakthroughs to advance the research and treatment of Alzheimer's disease and other dementias.

Register now to access exclusive member benefits:

- Year-round networking opportunities and informative webinars.
- 30 unique Professional Interest Areas (PIAs) that connect members with common subspecialties, providing a flexible forum to learn and collaborate.
- Discounted conference registration and extended abstract submission deadlines.
- Discounted publication fees for the Alzheimer's & Dementia journal family.
- Access to the ISTAART Career Center, an online jobs board curated for members.
- Free membership for individuals in low and middle income countries.

Become a member now at alz.org/ISTAART.

Questions? Contact ISTAART@alz.org.

INTERNATIONAL SOCIETY TO ADVANCE ALZHEIMER'S
RESEARCH AND TREATMENT (ISTAART)

ISTAART
ALZHEIMER'S ASSOCIATION